NASDAQ:ZYBT - Nasdaq - KYG989MS1016 - Common Stock - Currency: USD
NASDAQ:ZYBT (8/15/2025, 8:00:02 PM)
7.51
-0.1 (-1.31%)
The current stock price of ZYBT is 7.51 USD. In the past month the price increased by 31.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 43.42 | 664.58B | ||
JNJ | JOHNSON & JOHNSON | 17.66 | 425.41B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.83 | 245.46B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.04 | 240.45B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 13.4 | 232.88B | ||
MRK | MERCK & CO. INC. | 10.94 | 211.45B | ||
PFE | PFIZER INC | 7.42 | 142.93B | ||
SNY | SANOFI-ADR | 11.21 | 121.39B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 7.2 | 98.58B | ||
GSK | GSK PLC-SPON ADR | 8.61 | 79.42B | ||
ZTS | ZOETIS INC | 24.78 | 68.61B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 50 | 47.37B |
Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. The company is headquartered in Jilin, Jilin and currently employs 275 full-time employees. The company went IPO on 2025-01-07. The firm markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The firm owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The firm also engages in vaccines for treating livestock. The firm mainly conducts its business in the domestic market. The firm mainly conducts its business in the domestic and overseas market.
ZHENGYE BIOTECHNOLOGY HOLDIN
No.1 Lianmeng Street, Jilin Economic &, Technical Development Zone
Jilin JILIN CN
Employees: 275
The current stock price of ZYBT is 7.51 USD. The price decreased by -1.31% in the last trading session.
The exchange symbol of ZHENGYE BIOTECHNOLOGY HOLDIN is ZYBT and it is listed on the Nasdaq exchange.
ZYBT stock is listed on the Nasdaq exchange.
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a market capitalization of 355.90M USD. This makes ZYBT a Small Cap stock.
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) currently has 275 employees.
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a support level at 5.3 and a resistance level at 8.41. Check the full technical report for a detailed analysis of ZYBT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZYBT does not pay a dividend.
The PE ratio for ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 62.58. This is based on the reported non-GAAP earnings per share of 0.12 and the current share price of 7.51 USD. Check the full fundamental report for a full analysis of the valuation metrics for ZYBT.
The outstanding short interest for ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 5.91% of its float. Check the ownership tab for more information on the ZYBT short interest.
ChartMill assigns a technical rating of 5 / 10 to ZYBT.
ChartMill assigns a fundamental rating of 5 / 10 to ZYBT. Both the profitability and the financial health of ZYBT get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months ZYBT reported a non-GAAP Earnings per Share(EPS) of 0.12. The EPS increased by 21.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 12.95% | ||
ROA | 7.96% | ||
ROE | 13.83% | ||
Debt/Equity | 0.02 |